Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hepatic Portal System

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.

Oncology·2018

Same author

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2017

Same author

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.

Journal of hematology & oncology·2017

Same author

Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.

Oncotarget·2016

Same author

Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients.

Molecular and clinical oncology·2015

Same author

HER2/neu-directed therapy for biliary tract cancer.

Journal of hematology & oncology·2015

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Systemic therapy for hepatocellular carcinoma.

Melanie B Thomas¹

¹Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. methomas@mdanderson.org

Cancer Journal (Sudbury, Mass.)

|April 9, 2008

Summary

This summary is machine-generated.

Hepatocellular carcinoma (HCC), a common cancer, has rising incidence globally. Newer biologic agents targeting molecular abnormalities may improve outcomes for patients with advanced liver cancer.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Related Experiment Videos

Last Updated: Jul 6, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Area of Science:

Oncology
Hepatology
Cancer Research

Background:

Hepatocellular carcinoma (HCC) ranks as the fifth most common solid tumor globally and the third leading cause of cancer-related mortality.
While prevalent in developing nations, HCC incidence is increasing in developed regions like the US, Western Europe, and Japan.
Most patients (over 80%) are diagnosed with advanced or unresectable disease, and high recurrence rates (up to 50% at 2 years) follow resection.

Purpose of the Study:

To review the current landscape of systemic therapy for hepatocellular carcinoma.
To highlight the limitations of traditional chemotherapy in HCC patients with liver dysfunction.
To explore the potential of novel biologic agents targeting molecular pathways in HCC.

Main Methods:

Literature review of systemic therapies for HCC.
Analysis of current treatment guidelines and clinical trial data.
Evaluation of emerging biologic agents and their targeted mechanisms.

Main Results:

Systemic cytotoxic chemotherapy demonstrates limited efficacy and significant toxicity in HCC patients, particularly those with compromised liver function.
A substantial proportion of HCC patients require systemic therapy due to advanced stage or post-resection recurrence.
Emerging biologic agents offer a promising avenue for improving clinical outcomes by targeting specific molecular abnormalities in HCC.

Conclusions:

Traditional chemotherapy is largely ineffective for advanced hepatocellular carcinoma.
Novel biologic therapies targeting molecular pathways represent a promising strategy for improving treatment outcomes in HCC.
Further research and clinical trials are essential to establish the role of these newer agents in HCC management.